OBJECTIVE: To evaluate the feasibility and safety of single-port laparoscopically assisted vaginal hysterectomy (SP-LAVH) using transumbilical GelPort access. STUDY DESIGN: A prospective case-control study was performed at a University teaching hospital between January 2009 and March 2010, a total of 242 women with a uterus ≤16 weeks gestational size were enrolled in the study. Eighty women underwent SP-LAVH using transumbilical GelPort access (SP-LAVH group), and 162 women underwent conventional multiport LAVH (conventional LAVH group). RESULTS: There were no statistical differences between groups in the patients' demographic characteristics, median operating time (92.5 vs. 90 min; P=0.479), postoperative changes in hemoglobin concentration (1.4 vs. 1.4 g/dL; P=0.290), weight of the resected uterus (246 vs. 256 g; P=0.098), return of bowel activity (37.1 vs. 39.8h; P=0.103), hospital stay (3 vs. 3 days; P=0.554), complication rate (3.8 vs. 4.3%; P=1.000), and the rate of using an additional trocar or conversion to laparotomy (1.3 vs. 0.6%; P=0.553). CONCLUSIONS: SP-LAVH using transumbilical GelPort access is feasible and safe in women with a uterus ≤ 16 weeks gestational size. However, a large prospective randomized study is needed to confirm this conclusion and to establish guidelines for the use of SP-LAVH.
OBJECTIVE: To evaluate the feasibility and safety of single-port laparoscopically assisted vaginal hysterectomy (SP-LAVH) using transumbilical GelPort access. STUDY DESIGN: A prospective case-control study was performed at a University teaching hospital between January 2009 and March 2010, a total of 242 women with a uterus ≤16 weeks gestational size were enrolled in the study. Eighty women underwent SP-LAVH using transumbilical GelPort access (SP-LAVH group), and 162 women underwent conventional multiport LAVH (conventional LAVH group). RESULTS: There were no statistical differences between groups in the patients' demographic characteristics, median operating time (92.5 vs. 90 min; P=0.479), postoperative changes in hemoglobin concentration (1.4 vs. 1.4 g/dL; P=0.290), weight of the resected uterus (246 vs. 256 g; P=0.098), return of bowel activity (37.1 vs. 39.8h; P=0.103), hospital stay (3 vs. 3 days; P=0.554), complication rate (3.8 vs. 4.3%; P=1.000), and the rate of using an additional trocar or conversion to laparotomy (1.3 vs. 0.6%; P=0.553). CONCLUSIONS: SP-LAVH using transumbilical GelPort access is feasible and safe in women with a uterus ≤ 16 weeks gestational size. However, a large prospective randomized study is needed to confirm this conclusion and to establish guidelines for the use of SP-LAVH.
Authors: Evelien M Sandberg; Claire F la Chapelle; Marjolein M van den Tweel; Jan W Schoones; Frank Willem Jansen Journal: Arch Gynecol Obstet Date: 2017-03-29 Impact factor: 2.344